Showing 711-720 of 1321 results for "".
- NKTR-358 Demonstrates Proof of Concept in ADhttps://practicaldermatology.com/news/nktr-358-demonstrates-proof-of-concept-in-ad/2461011/Nektar Therapeutics and its partner Eli Lilly & Company’s NKTR-358 (LY3471851), a novel T regulatory (Treg) cell stimulator, demonstrated proof of concept in a Phase 1b study of patients with moderate-to-severe atopic dermatitis. The findings were presented at Eli Lilly&n
- FDA Accepts NDA for Boehringer Ingelheim’s Spesolimab for GPPhttps://practicaldermatology.com/news/fda-accepts-nda-for-boehringer-ingelheims-spesolimab-for-gpp/2461010/FDA has accepted a Biologics License Application (BLA) and granted Priority Review for Boehringer Ingelheim’s spesolimab for the treatment of generalized pustular psoriasis (GPP) flares. The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Bre
- Top Researcher of Itch and Inflammatory Skin Conditions to Join Mount Sinai’s Department of Dermatologyhttps://practicaldermatology.com/news/top-researcher-of-itch-and-inflammatory-skin-conditions-to-join-mount-sinais-department-of-dermatology/2461006/One of the top researchers worldwide studying itch and inflammatory skin conditions, Brian S. Kim, MD, MTR, FAAD, will join Mount Sinai Health System as Director of the newly established Mark Lebwohl Center for Neuroinflammation and Sensation. Dr. Kim will also be Vice Chair of Research of the Ki
- RoundTable Healthcare Partners Completes Sale of Revision Skincare and Goodier Cosmetics to Gryphon Investorshttps://practicaldermatology.com/news/roundtable-healthcare-partners-completes-sale-of-revision-skincare-and-goodier-cosmetics-to-gryphon-investors/2461000/RoundTable Healthcare Partners completed the previously announced sale of Revision Skincare and Goodier Cosmetics to Gryphon Investors. Terms of the transaction were not disclosed. Revision Skincare’s portfolio includes Nectifirm, Intellishade, D·E·J
- Alastin to be Acquired by Galdermahttps://practicaldermatology.com/news/alastin-to-be-acquired-by-galderma/2460997/Galderma is set to acquire Alastin Skincare®, Inc. The world’s largest independent dermatology company has signed a definitive agreement to acquire the specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. Financial
- FDA Clears New Lifting Indications for Sofwavehttps://practicaldermatology.com/news/new-indications-for-sofwave/2460996/Sofwave is now U.S. Food and Drug Administration (FDA)-cleared for lifting the eyebrow and lifting lax submental tissue and neck tissue in people aged 22 or older. In addition, the Sofwave system featuring the Company's proprietary Superb TM (Synchronous Ultrasound Parallel Be
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im